For Immediate Release
May 22, 2012

PHARMACOKINETICS PARAMETERS OF SUNSHINE BIOPHARMA'S LEAD ANTI-CANCER COMPOUND EXCEED EXPECTATIONS

Montreal, Quebec, Canada -- (*Canada Newswire*) -- Sunshine Biopharma Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed the pharmacokinetics studies in live rats for its lead anti-tumor compound, Adva-27a. Pharmacokinetics studies involve the determination of the fate of substances administered to a living organism. More specifically, pharmacokinetics refers to the study of the mechanisms of absorption and distribution of an administered drug, as well as the rate at which a drug action begins and the duration of the effect.

The pharmacokinetics studies Sunshine Biopharma recently completed analyzed the properties of Adva-27a and Etoposide in the plasma of live rats under a single intravenous bolus injection. While both Adva-27a and Etoposide had a mean terminal phase plasma half-life of approximately one hour, Adva-27a produced a 2.8-fold higher plasma initial concentration (C_0 = 8779 ng/mL) than Etoposide (C_0 = 3183 ng/mL). In addition, the area under the plasma concentration-versus-time curve for Adva-27a (AUC_{inf} = 2211 hr-ng/mL) was 2.4-times higher than that of Etoposide (AUC_{inf} = 933 hr-ng/mL). Moreover, Adva-27a had significantly lower plasma clearance rate (CL = 19.0 mL/min/kg) compared to Etoposide (CL = 44.7 mL/min/kg).

"These are very interesting results", said Dr. Steve N. Slilaty, Sunshine's President and CEO. "It appears that Adva-27a's pharmacokinetics profile is significantly better than that of Etoposide. This, together with our previous observation that Adva-27a is able to overcome multidrug resistance in breast cancer cells further confirms the uniqueness of Adva-27a as an anti-cancer compound," he added.

Sunshine Biopharma is currently conducting the next sequence of steps in its development of Adva-27a which include GMP manufacturing, IND-enabling studies, filing of an IND application followed by Phase I clinical trials in humans.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com